Increased prolactin levels are associated with impaired processing speed in subjects with early psychosis

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Montalvo, Itziar ^a   Gutiérrez Zotes, Alfonso ^a   Creus, Marta ^a   Monseny, Rosa ^a   Ortega, Laura ^a   Franch, Joan ^a   Lawrie, Stephen M ^b   Reynolds, Rebecca M ^c   Vilella, Elisabet ^a   Labad, Javier ^a  

^a UNIVERSITAT ROVIRA I VIRGILI   (Spain)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; BENZODIAZEPINE; HYDROCORTISONE; NEUROLEPTIC AGENT; PALIPERIDONE; PROLACTIN; RISPERIDONE; BENZODIAZEPINE DERIVATIVE; ISOXAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ADULT; ARTICLE; COGNITION; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE DURATION; DRUG USE; FEMALE; HIGH RISK PATIENT; HUMAN; HYDROCORTISONE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PROBLEM SOLVING; PROLACTIN BLOOD LEVEL; PSYCHOLOGIC ASSESSMENT; PSYCHOSIS; THINKING IMPAIRMENT; BLOOD; CASE CONTROL STUDY; CHEMICALLY INDUCED; COGNITIVE DEFECT; DRUG EFFECTS; HYPERPROLACTINEMIA; PATHOPHYSIOLOGY; PHYSIOLOGY; PSYCHOLOGICAL RATING SCALE; YOUNG ADULT;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CASE-CONTROL STUDIES; COGNITION; COGNITION DISORDERS; FEMALE; HUMANS; HYPERPROLACTINEMIA; ISOXAZOLES; MALE; PROLACTIN; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; PYRIMIDINES; YOUNG ADULT;

EID: 84896123510     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0089428     Document Type: Article

References (50)

1. Fitzgerald P, Dinan TG (2008) Prolactin and dopamine: What is the connection? A review article. J Psychopharmacol 22: 12-19.
2. Inder WJ, Castle D (2011) Antipsychotic-induced hyperprolactinaemia. Aust N Z J Psychiatry 45: 830-837.
3. Aston J, Rechsteiner E, Bull N, Borgwardt S, Gschwandtner U, et al (2010) Hyperprolactinaemia in early psychosis-not only due to antipsychotics. Prog Neuropsychopharmacol Biol Psychiatry 34: 1342-1344.
4. Garcia-Rizo C, Fernandez-Egea E, Oliveira C, Justicia A, Parellada E, et al (2012) Prolactin concentrations in newly diagnosed, antipsychotic-naive patients with nonaffective psychosis. Schizophr Res 134: 16-19.
5. Riecher-Rossler A, Rybakowski JK, Pflueger MO, Beyrau R, Kahn RS, et al (2013) Hyperprolactinemia in antipsychotic-naive patients with first-episode psychosis. Psychol Med : 1-12.
6. Lennartsson AK, Jonsdottir IH (2011) Prolactin in response to acute psychosocial stress in healthy men and women. Psychoneuroendocrinology 36: 1530-1539.
7. Halbreich U, Kahn LS (2003) Hyperprolactinemia and schizophrenia: Mechanisms and clinical aspects. J Psychiatr Pract 9: 344-353. (Pubitemid 37187616)
8. Johnsen E, Kroken R, Loberg EM, Kjelby E, Jorgensen HA (2011) Sexual dysfunction and hyperprolactinemia in male psychotic inpatients: A cross-sectional study. Adv Urol 2011: 686924.
9. Henry JF, Sherwin BB (2012) Hormones and cognitive functioning during late pregnancy and postpartum: A longitudinal study. Behav Neurosci 126: 73-85.
10. Torner L, Tinajero E, Lajud N, Quintanar-Stephano A, Olvera-Cortes E (2013) Hyperprolactinemia impairs object recognition without altering spatial learning in male rats. Behav Brain Res 252: 32-39.
11. Sherwin BB (2012) Estrogen and cognitive functioning in women: Lessons we have learned. Behav Neurosci 126: 123-127.
12. Wolf OT, Kirschbaum C (2002) Endogenous estradiol and testosterone levels are associated with cognitive performance in older women and men. Horm Behav 41: 259-266. (Pubitemid 34499453)
13. Bilder RM, Goldman RS, Robinson D, Reiter G, Bell L, et al (2000) Neuropsychology of first-episode schizophrenia: Initial characterization and clinical correlates. Am J Psychiatry 157: 549-559. (Pubitemid 30191193)
14. Heinrichs RW, Zakzanis KK (1998) Neurocognitive deficit in schizophrenia: A quantitative review of the evidence. Neuropsychology 12: 426-445. (Pubitemid 28323862)
15. Davidson M, Reichenberg A, Rabinowitz J, Weiser M, Kaplan Z, et al (1999) Behavioral and intellectual markers for schizophrenia in apparently healthy male adolescents. Am J Psychiatry 156: 1328-1335. (Pubitemid 29416527)
16. Reichenberg A, Weiser M, Rapp MA, Rabinowitz J, Caspi A, et al (2005) Elaboration on premorbid intellectual performance in schizophrenia: Premorbid intellectual decline and risk for schizophrenia. Arch Gen Psychiatry 62: 1297-1304. (Pubitemid 41746607)
17. Green MF (1996) What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 153: 321-330.
18. Cuesta MJ, Garcia de Jalon E, Campos MS, Ibanez B, Sanchez-Torres AM, et al (2012) Duration of untreated negative and positive symptoms of psychosis and cognitive impairment in first episode psychosis. Schizophr Res 141: 222-227.
19. Bilder RM, Goldman RS, Volavka J, Czobor P, Hoptman M, et al (2002) Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am J Psychiatry 159: 1018-1028. (Pubitemid 34586949)
20. Purdon SE, Malla A, Labelle A, Lit W (2001) Neuropsychological change in patients with schizophrenia after treatment with quetiapine or haloperidol. J Psychiatry Neurosci 26: 137-149. (Pubitemid 32373127)
21. Harvey PD. (2003) Ziprasidone and cognition: The evolving story. J Clin Psychiatry 64 Suppl 19: 33-39.
22. Keefe RS, Seidman LJ, Christensen BK, Hamer RM, Sharma T, et al (2004) Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: A randomized, double-blind trial of olanzapine versus low doses of haloperidol. Am J Psychiatry 161: 985-995. (Pubitemid 38735984)
23. Chew ML, Mulsant BH, Pollock BG, Lehman ME, Greenspan A, et al (2006) A model of anticholinergic activity of atypical antipsychotic medications. Schizophr Res 88: 63-72. (Pubitemid 44693242)
24. Mishara AL, Goldberg TE (2004) A meta-analysis and critical review of the effects of conventional neuroleptic treatment on cognition in schizophrenia: Opening a closed book. Biol Psychiatry 55: 1013-1022. (Pubitemid 38581917)
25. Woodward ND, Purdon SE, Meltzer HY, Zald DH (2007) A meta-analysis of cognitive change with haloperidol in clinical trials of atypical antipsychotics: Dose effects and comparison to practice effects. Schizophr Res 89: 211-224. (Pubitemid 44881296)
26. Maguire GA (2002) Prolactin elevation with antipsychotic medications: Mechanisms of action and clinical consequences. J Clin Psychiatry 63 Suppl 4: 56-62.
27. Cookson J, Hodgson R, Wildgust HJ (2012) Prolactin, hyperprolactinaemia and antipsychotic treatment: A review and lessons for treatment of early psychosis. J Psychopharmacol 26: 42-51.
28. Harvey PD, Keefe RS (2001) Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. Am J Psychiatry 158: 176-184. (Pubitemid 32116511)
29. Keefe RS, Silva SG, Perkins DO, Lieberman JA (1999) The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: A review and meta-analysis. Schizophr Bull 25: 201-222. (Pubitemid 29272501)
30. Carpenter WT, Gold JM (2002) Another view of therapy for cognition in schizophrenia. Biol Psychiatry 51: 969-971.
31. Yung AR, Phillips LJ, McGorry PD, McFarlane CA, Francey S, et al (1998) Prediction of psychosis. A step towards indicated prevention of schizophrenia. Br J Psychiatry Suppl 172: 14-20. (Pubitemid 28258893)
32. Wing JK, Babor T, Brugha T, Burke J, Cooper JE, et al (1990) SCAN. schedules for clinical assessment in neuropsychiatry. Arch Gen Psychiatry 47: 589-593. (Pubitemid 20189971)
33. Kay SR, Fiszbein A, Vital-Herne M, Fuentes LS (1990) The positive and negative syndrome scale-spanish adaptation. J Nerv Ment Dis 178: 510-517. (Pubitemid 20256607)
34. Addington D, Addington J, Schissel B (1990) A depression rating scale for schizophrenics. Schizophr Res 3: 247-251. (Pubitemid 20228720)
35. Gardner DM, Murphy AL, O'Donnell H, Centorrino F, Baldessarini RJ (2010) International consensus study of antipsychotic dosing. Am J Psychiatry 167: 686-693.
36. Nuechterlein KH, Green MF, Kern RS, Baade LE, Barch DM, et al (2008) The MATRICS consensus cognitive battery, part 1: Test selection, reliability, and validity. Am J Psychiatry 165: 203-213. (Pubitemid 351704520)
37. Rodriguez-Jimenez R, Bagney A, Garcia-Navarro C, Aparicio AI, Lopez-Anton R, et al (2012) The MATRICS consensus cognitive battery (MCCB): Conorming and standardization in spain. Schizophr Res 134: 279-284.
38. Baron RM, Kenny DA (1986) The moderator-mediator variable distinction in social psychological research: Conceptual, strategic, and statistical considerations. J Pers Soc Psychol 51: 1173-1182.
39. Shrout PE, Bolger N (2002) Mediation in experimental and nonexperimental studies: New procedures and recommendations. Psychol Methods 7: 422-445.
40. Preacher KJ, Hayes AF (2008) Asymptotic and resampling strategies for assessing and comparing indirect effects in multiple mediator models. Behav Res Methods 40: 879-891.
41. Dickinson D, Ramsey ME, Gold JM (2007) Overlooking the obvious: A metaanalytic comparison of digit symbol coding tasks and other cognitive measures in schizophrenia. Arch Gen Psychiatry 64: 532-542. (Pubitemid 46718286)
42. Riecher-Rossler A, Pflueger MO, Aston J, Borgwardt SJ, Brewer WJ, et al (2009) Efficacy of using cognitive status in predicting psychosis: A 7-year follow-up. Biol Psychiatry 66: 1023-1030.
43. Ojeda N, Pena J, Sanchez P, Elizagarate E, Ezcurra J (2008) Processing speed mediates the relationship between verbal memory, verbal fluency, and functional outcome in chronic schizophrenia. Schizophr Res 101: 225-233.
44. Dickinson D (2008) Digit symbol coding and general cognitive ability in schizophrenia: Worth another look? Br J Psychiatry 193: 354-356.
45. Kelleher I, Murtagh A, Clarke MC, Murphy J, Rawdon C, et al (2012) Neurocognitive performance of a community-based sample of young people at putative ultra high risk for psychosis: Support for the processing speed hypothesis. Cogn Neuropsychiatry.
46. Fusar-Poli P, Bonoldi I, Yung AR, Borgwardt S, Kempton MJ, et al (2012) Predicting psychosis: Meta-analysis of transition outcomes in individuals at high clinical risk. Arch Gen Psychiatry 69: 220-229.
47. Lee BJ, Lee SJ, Kim MK, Lee JG, Park SW, et al (2013) Effect of aripiprazole on cognitive function and hyperprolactinemia in patients with schizophrenia treated with risperidone. Clin Psychopharmacol Neurosci 11: 60-66.
48. Stewart SA (2005) The effects of benzodiazepines on cognition. J Clin Psychiatry 66 Suppl 2: 9-13.
49. Zhang X, Bu R, Sha W, Wang X, Liu J, et al (2013) Serum prolactin and smoking status in chronic antipsychotic-treated male patients with schizophrenia. Psychiatry Res 209: 239-241.
50. Segarra R, Zabala A, Eguiluz JI, Ojeda N, Elizagarate E, et al (2011) Cognitive performance and smoking in first-episode psychosis: The self-medication hypothesis. Eur Arch Psychiatry Clin Neurosci 261: 241-250.